Dermira, Inc. (NASDAQ:DERM) currently has an Average Broker Rating of 1.67. The ABR rank within the industry stands at 20. This number is based on the 6 sell-side firms polled by Zacks.
Successfully tackling the equity markets may involve owning a wide range of stocks. Some investors may prefer growth stocks while others may opt for value stocks. Having a good mix of both types may help build of solid foundation for the portfolio. Investors may choose stocks in a specific industry that is gaining strength. If the industry is on the rise, the portfolio may be more likely to succeed. Finding companies that are considered leaders in their field may also be on the investor checklist. A company that has a large presence may help ease investor worry, especially in a down market climate. Finding the perfect stocks to add to the portfolio may not always be easy, and in fact it may be quite difficult. Investors may have to lay out goals to help keep things on track for both the short-term and the long haul.
Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR.
As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.
Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.
For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.
Analysts on a consensus basis are expecting that the stock will reach $47 within the year.
Most recently Dermira, Inc. (NASDAQ:DERM) posted quarterly earnings of $-0.93 which compared to the sell-side estimates of -0.85. The stock’s 12-month trailing earnings per share stands at $-2.65. Shares have moved $-11.71 over the past month and more recently, $-2.68 over the past week heading into the earnings announcement. There are 2 analyst projections that were taken into consideration from respected brokerage firms.
Traders are often looking for any little advantage that they can get when attempting to grab profits in the stock market. Traders might be closely watching insider buying and selling as well as what the successful fund managers are doing. Following the smart money can help investors get a grasp on the bigger picture of what is going on with certain equities. There is no shortage of information that the individual trader can get their hands on. Figuring out how to best put that information to work is an important part of any trading plan. With so much data to track, traders may need to decide which information they will use when making the big investing decisions. Pinpointing the next great trade could be just around the corner, but it may take some hard work and enhanced focus.
Research analysts are predicting that Dermira, Inc. (NASDAQ:DERM) will report earnings of $-1.12 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Dermira, Inc. (NASDAQ:DERM) closed the last session at $23.59 and sees an average of 458304.69 shares trade hands in each session. The 52-week low of the stock stands at $22.43 while the current level stands at 7.44% of the 52-week High-Low range. Looking further out we can see that the stock has moved -14.68% over the past 12 weeks and -22.22% year to date.
5 analysts rate Dermira, Inc. a Buy or Strong Buy, which is 83.33% of all the analyst ratings.
Investors will be closely watching which way market momentum will shift as we cruise into the back half of the year. Earnest investors will most likely be pouring over the latest earnings reports trying to spot buying opportunities. Many investors will pay especially close attention to companies that have posted large surprise factors over the past quarter. As the dust settles, investors might be monitoring stock price activity following the earning release in order to set up a plan for trading around the next earnings season.